India's Glenmark Gets Arbitrator Nod to Sell HIV-Associated Diarrhea Drug
September 4, 2012
The International Center for Dispute Resolution has ruled that India's Glenmark Pharmaceuticals has the right to sell Crofelemer, its drug for HIV-associated diarrhea, in 140 countries. The medication was developed by Glenmark with U.S.-based partners Napo Pharmaceuticals and Salix Pharmaceuticals Ltd. Glenmark sought arbitration in the United States in December, after Napo terminated a three-party agreement that gave Glenmark exclusive distribution rights for Crofelemer in India and 139 other nations. In a statement, Glenmark said the ICDR found that Napo breached the agreement by revealing confidential information about manufacturing Crofelemer to Aptuit Laurus, another drugmaker. Glenn Saldanha, Glenmark's chair, said the ruling will permit the company "to further its commitment to working with relief agencies to distribute Crofelemer to affected populations."
Approval of Fulyzaq (Crofelemer) to Relieve Symptoms of Diarrhea in HIV/AIDS Patients Taking Antiretroviral Therapy
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)